Clinical effect of alprostadil combined with epalrestat on diabetic foot

Zhang Liang; Zhang Jichun; Pang Zixuan; Wang Yubing

doi:10.3760/j.issn.1673-4777.2019.10.018

Abstract：Objective To explore the effect of alprostadil combined with epalrestat on patients with diabetic foot. Methods A total of 114 patients with diabetic foot admitted to the Seventh People′s hospital of Hebei Province from December 2016 to December 2017 were randomly divided into control group and observation group, with 57 cases in each group. The control group was treated with routine therapy and nursing care. The observation group was treated with alprostadil combined with epalrestat on the basis of routine treatment. Wound healing was assessed 2 and 4 weeks after treatment. Hemodynamics of dorsal pedal artery and conduction velocity of common peroneal nerve of affected limb, levels of tumor necrosis factor-α(TNF-α), interleukin-6(IL-6) and vascular endothelial growth factor( VEGF) in granulation tissue were detected after treatment. Results The 2-and 4-week wound healing rates in observation group were significantly higher than those in control group [ ( 23. 6 ± 2.2)％ vs (15.4 ±2.4)％, (41.9 ±4.2)％ vs (29.6 ±3.8)％](P<0.01). After treatment, blood flow ve-locity and diameter of dorsal pedal artery and conduction velocity of common peroneal nerve in observation group were higher than those in control group;levels of TNF-αand IL-6 in granulation tissue were lower and VEGF level was higher in observation group than those in control group(all P<0. 05). Conclusion Alprostadil combined with epalrestat treating diabetic foot can significantly improve hemodynamics of dorsal pedal artery and conduction velocity of common peroneal nerve, reduce TNF-α and IL-6 and increase VEGF in granulation tissue, improve microcirculation and promote wound healing.